Impact of Screening Patients With HIV for Kidney Disease

This study has been withdrawn prior to enrollment.
(Sufficient study funding was not obtained.)
Sponsor:
Information provided by:
University of Mississippi Medical Center
ClinicalTrials.gov Identifier:
NCT00392132
First received: October 23, 2006
Last updated: November 24, 2008
Last verified: November 2008

October 23, 2006
November 24, 2008
October 2005
October 2006   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00392132 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Screening Patients With HIV for Kidney Disease
Impact of Screening Patients With HIV for Kidney Disease

The Infectious Disease Society of America has recently recommended that patients with Human Immunodeficiency Virus (HIV) be screened for kidney disease on a regular basis. Screening involves non-invasive urine and blood test and a screening program has already been initiated here in the University of Mississippi HIV clinic. This study looks at the effect of this new screening program. Our Hypothesis is that screening for kidney disease is a cost effective and important addition to the care of patients with HIV.

The Infectious Disease Society of America has recently recommended that patients with Human Immunodeficiency Virus (HIV) be screened for kidney disease on a regular basis. Screening involves non-invasive urine and blood test and a screening program has already been initiated here in the University of Mississippi HIV clinic. However nobody knows for sure whether this will help doctors take better care of patient with HIV.

This study looks at the effect of this new screening program. We want to see how frequently abnormalities are seen on screening, how frequently certain kidney diseases are diagnosed, how often patients are referred to a nephrologist and how often a patient's management is changed by the screening. We will also estimate the cost-benefit ratio of the screening. We will review patient charts to determine what has happened in each case where screening was conducted.

This study will not involve any additional testing.

The benefit of this study will be improving our understanding of kidney disease in HIV. It will help us determine the value of screening for kidney disease and the frequency of certain kidney diseases in HIV in our clinic population.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • HIV Infections
  • Renal Insufficiency, Chronic
  • Proteinuria
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
1400
October 2006
October 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients with HIV who are seen by the University of Mississippi Infectious disease clinic at the Jackson Medical Mall or patient seen at the University of Mississippi Nephrology Clinic.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00392132
UMMC - HIV and CKD
Not Provided
Darren Schmidt, Assistant Professor of Medicine, University of Mississippi Medical Center
University of Mississippi Medical Center
Not Provided
Principal Investigator: Darren W Schmidt, MD University of Mississippi Medical Center
University of Mississippi Medical Center
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP